- NLM Classification (20)
- WJ Urogenital system (20)
- WJ 300-378 Kidney (20)
- WJ Urogenital system (20)
Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.
Fischer, S. and Kisser, A. (2015): Robot-assisted surgery: A systematic review of effectiveness and safety for elected indications and accumulating costs. HTA-Projektbericht 84.
Fischer, S. and Warmuth, M. (2012): Radiofrequency Ablation for the Treatment of Tumours of the Urogenital Tract (Renal Cell Carcinoma, Prostate Cancer and Uterine Leiomyoma). Decision Support Document 59.
Geiger-Gritsch, S. (2007): [Avastin® (Bevacizumab): Off-label use in cancer therapy]. HTA-Newsletter 58: p. 2.
Goetz, G. and Giess, D. and Kern, J. (2024): Renal denervation (RDN) in patients with treatment resistant hypertension. Decision Support Document 45/ 2. Update 2024.
Grössmann, N. (2021): Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Update August 2021. Oncology Fact Sheet Nr. 42.
Hintringer, K. (2010): Pazopanib (Votrient®) for the treatment of locally advanced and/or metastatic renal cell carcinoma. DSD: Horizon Scanning in Oncology 13.
Mathis, S. and Winkler, R. and Geiger-Gritsch, S. and Mittermayr, T. (2009): Selective IgG Apheresis for ABO-incompatible kidney transplantation. Systematic Review. Decision Support Document 25.
Nachtnebel, A. (2009): Everolimus (Afinitor®) for advanced/metastatic kidney cancer. DSD: Horizon Scanning in Oncology 03.
Poggiani, C. and Hintringer, K. (2012): Axitinib (AG013736, Inlyta®) for the second-line treatment of metastatic renal cell carcinoma (mRCC) . DSD: Horizon Scanning in Oncology 21.
Reichel, M. and Zechmeister-Koss, I. (2012): Renal denervation in patients with essential hypertension . Decision Support Document 45 / Update 2012.
Riegelnegg, M. and Gassner, L. and Grössmann-Waniek, N. (2023): Robot-assisted surgery in thoracic and visceral indications – Update 2023. HTA-Projektbericht 108/ Update 2023.
Rothschedl, E. (2018): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC. DSD: Horizon Scanning in Oncology 82.
Wild, C. (2007): [FDA: Safety warning on erythropoietin]. HTA-Newsletter 58: p. 4.
Wild, C. (2004): [CT and MR angiography. Diagnostics of renal artery stenosis]. HTA-Newsletter 27: pp. 3-4.
Wild, C. (2003): [Ambulatory versus stationary haemodialysis for people with end-stage renal failure]. HTA-Newsletter 20: p. 4.
Wild, C. (2003): [MARS® liver support]. HTA-Newsletter 20: p. 2.
Wild, C. (2007): [FDA: Safety warning on erythropoietin]. ÖKZ: Österreichische Krankenhauszeitung 48 (07).
Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of renal cell carcinoma (RCC). Update March 2022. Oncology Fact Sheet Nr. 74.
Wolf, S. (2021): Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC). Update January 2022. Oncology Fact Sheet Nr. 67.